Vaxart (VXRT) said Wednesday the phase 1 trial of its second-generation oral norovirus vaccine pills has met its primary immunological endpoint.
The study compared the new, second-generation vaccine candidate with the older, first-generation version in 60 healthy volunteers, the company said.
According to the company, people who received the higher dose of the new vaccine had much higher antibody levels than those who got the older vaccine.
Meanwhile, all versions of the treatment were found safe and well-tolerated, with no serious side effects linked to the drug.
The company said it expects to start a phase 2b study in late 2025, depending on funding or partnerships, and could begin a phase 3 trial as early as 2026.
Shares of the company were up more than 38% in recent trading.
Price: 0.55, Change: +0.15, Percent Change: +38.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.